The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

• Status: Completed
• Trial end date: 2011-01-01

Summary

To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)

• Phase: Phase 2

Details

• Lead Sponsor: ThromboGenics
• Treatments: Fibrinolysin; Plasminogen; Temazepam